Health Catalyst, INC Form 4 insider transactions

Health Catalyst CEO Daniel D. Burton sold 30,897 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Health Catalyst's Chief Operating Officer, Daniel LeSueur, sold 10,455 shares of common stock to cover tax obligations related to vesting restricted stock units.

Health Catalyst's Chief People Officer, Linda Llewelyn, sold 7,766 shares of common stock to cover tax obligations related to vesting restricted stock units.

Anita Pramoda, a director at Health Catalyst, acquired 1,847 shares of common stock through the vesting of restricted stock units on December 1, 2024.

Director Julie Larson-Green acquired 1,616 shares of Health Catalyst stock through the vesting of restricted stock units on December 1, 2024.

Health Catalyst director Duncan Gallagher acquired 2,001 shares of common stock through the vesting of restricted stock units.

Linda Llewelyn, Chief People Officer of Health Catalyst, sold 1,365 shares of common stock at $8.50 per share on November 15, 2024, under a pre-arranged 10b5-1 trading plan.

Health Catalyst's Chief Operating Officer, Daniel LeSueur, sold 5,209 shares of common stock at a price of $7.7034 per share on November 5, 2024, under a pre-arranged 10b5-1 trading plan.

Linda Llewelyn, Chief People Officer of Health Catalyst, Inc., sold 1,324 shares of common stock at a price of $8.16 per share on October 15, 2024, under a pre-arranged trading plan.

Health Catalyst's Chief Operating Officer, Daniel LeSueur, sold 5,209 shares of common stock at a price of $7.6812 per share on October 3, 2024.

Linda Llewelyn, Chief People Officer of Health Catalyst, Inc., sold 1,324 shares of common stock at $8.43 per share on September 16, 2024, under a pre-arranged trading plan.

Health Catalyst's General Counsel, Benjamin Landry, sold 2,466 shares of common stock at $7.3891 per share on September 6, 2024, under a pre-arranged trading plan.

Anita Pramoda, a director at Health Catalyst, Inc., reports acquiring 2,228 shares of common stock through restricted stock units that vested on September 1, 2024.

Julie Larson-Green, a director at Health Catalyst, Inc., acquired 1,950 shares of common stock on September 1, 2024, through the vesting of restricted stock units (RSUs).

Director Duncan Gallagher acquired 2,414 shares of Health Catalyst, Inc. common stock through a restricted stock unit (RSU) award that vested on September 1, 2024.

Health Catalyst's CFO, Jason Alger, sold 2,899 shares of common stock at a price of $7.3911 per share on September 6, 2024, under a pre-arranged trading plan.

Benjamin Landry, General Counsel of Health Catalyst, Inc., sold 1,222 shares of common stock on September 3, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Daniel LeSueur, COO of Health Catalyst, Inc., sold shares to cover tax obligations and pursuant to a pre-arranged trading plan.

Kevin Lee Freeman, Chief Commercial Officer of Health Catalyst, Inc., sold shares to cover tax obligations and pursuant to a pre-arranged trading plan.

Health Catalyst CEO Daniel D. Burton sold 4,174 shares of common stock on September 3, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Linda Llewelyn, Chief People Officer of Health Catalyst, Inc., sold 1,613 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Jason Alger, CFO of Health Catalyst, Inc., sold 1,165 shares of common stock on September 3, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Linda Llewelyn, Chief People Officer of Health Catalyst, Inc., sold 1,328 shares of common stock at $6.57 per share on August 15, 2024, under a pre-arranged trading plan.

Health Catalyst's Chief Operating Officer, Daniel LeSueur, sold 5,209 shares of common stock at a price of $6.1863 per share on August 5, 2024, under a pre-arranged trading plan.

Linda Llewelyn, Chief People Officer of Health Catalyst, Inc., sold 1,290 shares of common stock at $6.51 per share on July 15, 2024, under a pre-arranged trading plan.

Health Catalyst's Chief Operating Officer, Daniel LeSueur, sold 5,208 shares of common stock at a price of $6.1538 per share on July 3, 2024, under a pre-arranged 10b5-1 trading plan.

Linda Llewelyn, Chief People Officer of Health Catalyst, Inc., sold 1,290 shares of common stock at a price of $6.3725 per share on June 17, 2024, under a pre-arranged 10b5-1 trading plan.

Director Duncan Gallagher of Health Catalyst, Inc. was granted 20,807 Restricted Stock Units (RSUs) on June 13, 2024.

Director John A. Kane received 20,807 shares of Health Catalyst, Inc. common stock on June 13, 2024, as part of a restricted stock unit (RSU) award.

Julie Larson-Green, a director at Health Catalyst, Inc., was granted 20,807 Restricted Stock Units (RSUs) on June 13, 2024, according to a Form 4 filing.